Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China

BACKGROUND: Although pembrolizumab is recommended as a first-line treatment for advanced recurrent/unresectable/metastatic (R/U/M) head and neck squamous carcinoma, the differences in its efficacy among different populations need to be investigated. METHODS: We reviewed 15 consecutive patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jieying, He, Zongxuan, Tao, Yueqin, Yang, Xiaochen, Ge, Shengyou, Xu, Haoyue, Shang, Wei, Song, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229243/
https://www.ncbi.nlm.nih.gov/pubmed/37261276
http://dx.doi.org/10.1155/2022/7283946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229243/
https://www.ncbi.nlm.nih.gov/pubmed/37261276
http://dx.doi.org/10.1155/2022/7283946

Ejemplares similares